Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00413231 · ClinicalTrials.gov registry record · NA

Valor II: The Valiant Thoracic Stent Graft System Clinical Study

A NA study of Thoracic Aortic Aneurysm, sponsored by Medtronic Cardiovascular.

Completed
Registry status
NA
Development phase
160
Enrollment target
20
Study locations

NCT00413231: Completed NA study of Thoracic Aortic Aneurysm, sponsored by Medtronic Cardiovascular.

NCT00413231 is a NA study of Thoracic Aortic Aneurysm that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 160 participants, below the 889-participant average among 7 other Thoracic Aortic Aneurysm trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00413231, a NA study of Thoracic Aortic Aneurysm, has completed, sponsored by Medtronic Cardiovascular.

COMPLETED
Registry status
NA
Development phase
160 participants
Enrollment target
20
Study locations

Study Summary

This study was designed to study safety and effectiveness of the Valiant Thoracic Stent Graft to treat thoracic aortic aneurysms.

Primary Outcome

Evaluation of the ARM-free rate in subjects implanted with the Valiant Thoracic Stent Graft five years post-implantation by comparing it to a pre-defined performance goal (PG) based on an analysis of ARM-free rates from TEVAR data and on results from the VALOR (Talent Thoracic Endoluminal Stent Graft, IDE G980116) clinical study.

Conditions Studied

Interventions

  • DEVICE Valiant Thoracic Stent Graft System

Study Locations (20)

New York

  • Albany Medical Center - Albany
  • New York University Medical Center - New York
  • Mount Sinai School of Medicine - New York

California

  • University of Southern California - Healthcare Consultation Center - Los Angeles
  • Los Angeles Biomedical Research Institute @ Harbor-UCLA Medical Center - Torrance

Florida

  • University of Florida - Gainesville
  • University of South Florida - Tampa

Alabama

  • University of Alabama at Birmingham - Birmingham

Connecticut

  • Hartford Hospital - Hartford

Georgia

  • Emory University Hospital - Atlanta

Illinois

  • Loyola University Medical Center - Maywood

Maryland

  • Union Memorial - Baltimore

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2006-12
Est. Completion 2014-10
Phase NA
Medtronic Cardiovascular

44 total trials

What the finished NCT00413231 record still lists

NCT00413231 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 889-participant average among 7 other Thoracic Aortic Aneurysm trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Thoracic Aortic Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which Valiant Thoracic Stent Graft System is the first listed.

NCT00413231 names 20 study sites across 16 states, led by New York, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00413231 about?

NCT00413231 is a clinical study titled "Valor II: The Valiant Thoracic Stent Graft System Clinical Study". This study was designed to study safety and effectiveness of the Valiant Thoracic Stent Graft to treat thoracic aortic aneurysms.

What is the current status of trial NCT00413231?

This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2006-12. Estimated completion is 2014-10.

What conditions does trial NCT00413231 study?

This clinical trial studies the following conditions: Thoracic Aortic Aneurysm.

What interventions are being tested in trial NCT00413231?

The interventions under investigation include: Valiant Thoracic Stent Graft System (DEVICE).

Who is sponsoring clinical trial NCT00413231?

This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00413231 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Thoracic Aortic Aneurysm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00413231, the US trial registry maintained by the National Library of Medicine. NCT00413231 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.